IPP Bureau
AIIMS organises consultation on ‘C2IQ’
By IPP Bureau - December 29, 2022
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
CDSCO and State Drugs Control Administration commence joint inspection of drug manufacturing units
By IPP Bureau - December 28, 2022
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
Mandaviya visits Safdarjung Hospital; Reviews mock drill for ensuring readiness for COVID-19 management
By IPP Bureau - December 28, 2022
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
Aurobindo's subsidiary Tergene Biotech receives SEC recommendation for pneumococcal 15 valent vaccine
By IPP Bureau - December 28, 2022
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Amcor sells factories in Russia
By IPP Bureau - December 28, 2022
The cash and debt free consideration value is €370 million.
Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
By IPP Bureau - December 28, 2022
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
By IPP Bureau - December 27, 2022
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Alembic receives USFDA final approval for Fulvestrant Injection
By IPP Bureau - December 27, 2022
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Hetero's COVID-19 oral drug gets WHO prequalification
By IPP Bureau - December 27, 2022
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData
By IPP Bureau - December 27, 2022
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
ESIC plans to fill 6,400 vacancies including posts for more than 2,000 doctors and teaching faculty: Bhupender Yadav
By IPP Bureau - December 26, 2022
The organisation is also working towards providing skills based training programmes to the workers for paramedical jobs and has launched certificate courses in ten disciplines
Center advises states to be on alert and keep all preparedness for COVID-19 management: Dr. Mandaviya
By IPP Bureau - December 26, 2022
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Briefs: J. B. Chemicals & Pharmaceuticals, Dr. Reddy’s Laboratories and Piramal Enterprises
By IPP Bureau - December 26, 2022
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Advent International to acquire a significant stake in Suven Pharmaceuticals
By IPP Bureau - December 26, 2022
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
